Researchers from the Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have identified a critical quality attribute that potentially allows the development of a rapid and sensitive process analytical technology for sterility. Specifically, this technology enables the detection of early-stage microbial contamination in human cell therapy products.
To learn more, read the full article via MIT News. The recent paper where this work is described, “The ratio of nicotinic acid to nicotinamide as a microbial biomarker for assessing cell therapy product sterility” is published in Molecular Therapies; Methods & Clinical Development, April 23, 2022.
